Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin and Donepezil in Alzheimer's Disease
NCT00911807Phase 2Completed
- Sponsor
- EVER Pharma
- Start
- Oct 2004
- Primary completion
- Apr 2008
- Modality
- Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Cerebrolysin + donepezil, Cerebrolysin + placebo and Donepezil + placebo (3 arms). Primary endpoints: Alzheimer's Disease Assessment Scale Cognitive Subpart (Extended Version) at 28 weeks and Clinical Interview-based Impression of Change at 28 weeks. Started Oct 2004; status: completed.
02
Drugs
cerebrolysin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00911807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00911807.